NeoStem's Subsidiary, Progenitor Cell Therapy, to Provide Autologous and Allogeneic Cellular Therapy Services to MedStar Georgetown University Hospital

Details

Hits: 21

Allendale, N.J. and Washington, D.C., May 13, 2013 -- NeoStem, Inc. (NYSE MKT:NBS), a leader in the emerging cellular therapy industry, and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized contract development and manufacturing organization, announced today that PCT has entered into a Cell Therapy Processing Customer Agreement with MedStar Georgetown University Hospital in Washington, D.C. to provide autologous and allogeneic cellular therapy services for cellular products provided by MedStar Georgetown University Hospital ("MGUH") and deliver resulting cellular therapy products to MGUH for patient care.

In April, Georgetown's Lombardi Comprehensive Cancer Center, part of MedStar Georgetown University Hospital, and the John Theurer Cancer Center, part of Hackensack University Medical Center ("HackensackUMC") in Hackensack, N.J., announced the establishment of an oncology affiliation arrangement between them to enhance patient access to innovative clinical trials, and is a significant step towards developing a clinical, translational and basic science cancer research consortium.

Read more...

Preclinical Research Shows PLX Cells May Be Effective in Treating Preeclampsia

Details

Hits: 28

No treatment exists today for the most common medical complication of pregnancy

HAIFA, Israel May 13, 2013 — Pluristem Therapeutics Inc. (NASDAQCM: PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today its PLacental eXpanded (PLX) cells tested in preclinical animal models of preeclampsia effectively improved several parameters of the disease. The study was conducted in collaboration with Brett Mitchel PhD, Associate Professor of Internal Medicine at the Cardiovascular Research Institute (CVRI) of the Texas A&M College of Medicine. Dr. Mitchel will present details of the study on May 30^th at the Society for Gynecological Investigation Summit in Jerusalem.

Preeclampsia is the most common medical complication of pregnancy and a leading cause of premature births, stillbirths and early neonatal and maternal deaths. If left untreated, it can develop into eclampsia, the life-threatening occurrence of seizures during pregnancy. The only known treatment for eclampsia or preeclampsia is abortion or delivery. The disease occurs in previously healthy women after their 20^th week of pregnancy and symptoms include high blood pressure and significant amounts of protein in the urine. According to the World Health Organization, preeclampsia occurs in approximately 6–8% of pregnancies worldwide. It is estimated that preeclampsia costs the global health care system $3 billion annually. May was recognized as National Preeclampsia Awareness Month by U.S. Congresswomen in an effort to improve outcomes for women and babies.

Read more...

Md Stem Cells Continues Billion Cell Treatments for Eye Disease

Details

Hits: 23

Fort Lauderdale, FL, May 11, 2013 –(PR.com)– Bigger is typically better. That is especially true in regenerative medicine where a larger number of stem cells likely provides greater benefit for the patients.

“We’re pleased to report that we are continuing to see billion plus cell harvests during our bone marrow aspirations. In lab testing following our most recent stem cell treatments in Florida, the cell counts on the delivered stem cell treatments remain far above our expectations,” exclaimed Dr. Levy, President of MD Stem Cells. "We continue to have very high total nucleated cell counts following separation using our FDA cleared class 2 device. We attribute these significant counts to our excellent board certified orthopedic surgeon and his superb harvest technique. The more stem cells available, the greater the numbers which are available for treating retina and optic nerve eye problems. When we received the more recent reports back we were extremely pleased."

Read more...

Stem cell research for new MS treatment

Details

Hits: 49

Friday, 10 May 2013

Modified adult stem cells may hold the key to a new treatment for multiple sclerosis, according to University of Adelaide researchers, speaking during 'Kiss Goodbye to MS' month.

The researchers have started a three-year research project using adult stem cells from fat tissue to send cells with special anti-inflammatory properties directly to the damaged site in the central nervous system (CNS).

Multiple sclerosis is an autoimmune inflammatory disease of the brain and spinal cord. To control the disease, effective treatments need to control the immune response and repair the damage caused to the fatty myelin sheaths which protect the nerves.

Read more...